Iovance Biotherapeutics to Present at 2023 Wells Fargo Healthcare Conference
07. September 2023 07:31 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor...
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
18. August 2023 17:00 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor...
Iovance Biotherapeutics Reports Second Quarter and First Half 2023 Financial Results and Corporate Updates
08. August 2023 16:01 ET
|
Iovance Biotherapeutics, Inc.
FDA Priority Review of Biologics License Application (BLA) on Track for Lifileucel in Advanced Melanoma with Prescription Drug User Fee Act (PDUFA) Action Date of November 25, 2023 Preparing for...
Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy at IASLC 2023 World Conference on Lung Cancer
25. Juli 2023 16:01 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor...
Iovance Biotherapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, August 8, 2023
24. Juli 2023 16:01 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor...
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
21. Juli 2023 17:34 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., July 21, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor...
Iovance Biotherapeutics Announces Closing of $172.5 Million Common Stock Public Offering
13. Juli 2023 16:01 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor...
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock
10. Juli 2023 21:46 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) (“Iovance” or “Company”), a biotechnology company focused on innovating, developing, and delivering...
Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock
10. Juli 2023 16:34 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) (“Iovance” or “Company”), a biotechnology company focused on innovating, developing, and delivering...
Iovance Biotherapeutics Announces Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung Cancer
10. Juli 2023 07:00 ET
|
Iovance Biotherapeutics, Inc.
Positive FDA Feedback Supports IOV-LUN-202 Trial Design for Accelerated Approval of TIL Therapy in Post-Anti-PD-1 Advanced Non-Small Cell Lung Cancer (NSCLC) Preliminary Clinical Data in...